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Expert Opinion
Despite the fact that more than 20 years have passed since the clinical 
introduction of cardiac resynchronisation therapy (CRT), one of the 
key questions – do we need an ICD for primary prevention of sudden 
cardiac death (SCD) in CRT patients? – is still unanswered.
Prospective Randomised Controlled Trials
Multiple prospective randomised controlled trials have been conducted 
to establish the use of CRT in different categories of heart failure 
patients; these studies have consistently demonstrated the superiority 
of CRT compared with best medical therapy in improving ventricular 
function, the patient’s functional capacity, and prognosis. The greatest 
majority of prospective randomised controlled studies used a CRT 
device combined with an ICD (CRT-D). 
Indeed, past prospective randomised controlled trials of primary 
prevention in patients with heart failure indicated that ICD reduced 
mortality in post-MI patients with left ventricular ejection fraction 
(LVEF) <30 % (Multicentre Automatic Defibrillator Implantation Trial 
II; MADIT II),1 and ischaemic or non-ischaemic cardiomyopathy in 
patients with LVEF <35  % (Sudden Cardiac Death in Heart Failure 
Trial; SCD-HeFT).2
In patients with LVEF <35 %, advanced heart failure (New York Heart 
Association; NYHA class III or IV) due to ischaemic or non-ischaemic 
cardiomyopathies and a QRS interval >120 ms, the presence of ICD 
capabilities reduced mortality (Comparison of Medical Therapy, Pacing, 
and Defibrillation in Heart Failure trial; COMPANION).3 Of note, the 
addition of CRT to patients who already require an ICD also reduces 
mortality.
In the Resynchronisation–Defibrillation for Ambulatory Heart Failure 
Trial (RAFT) in patients with NYHA II or III heart failure, LEVF ≤30 %, and 
a QRS ≥120 ms or paced QRS ≥200 ms, the addition of CRT to an ICD 
improved survival, albeit at a cost of increased implantation-related 
complications (RAFT).4 In the MADIT with Cardiac Synchronisation 
Therapy (MADIT-CRT), in patients with ischaemic (NYHA I or II) or 
non-ischaemic (NYHA II) cardiomyopathy, LVEF ≤30  %, and QRS≥ 130 
ms with left bundle branch block morphology, CRT offered a 11  % 
reduction in mortality compared with an ICD alone.5 In a real-world 
retrospective cohort study using National Cardiovascular Registry 
data linked with Medicare claims, patients who were eligible for 
CRT-D according to established criteria and who received CRT-D had 
significantly lower risks for death and readmission than those who 
received an ICD therapy alone.6
Clinical Daily Practice
All that, however, contrasts with clinical daily practice in which 
approximately one-third of patients receive a CRT without an ICD 
function (CRT-P). The clinical justification to offer a sizable group of 
patients a CRT-P device is given by the lack of a perceived realistic, 
additional survival benefit, as provided by an ICD, in addition to what 
may be achieved by CRT-P alone. Clinical factors possibly associated 
with higher mortality due to heart failure rather than SCD (the latter can 
be effectively reduced only by an ICD) are advanced age, cardiovascular 
comorbidities, some neurological diseases associated with severe 
cognitive and/or physical impairment, psychiatric disorders, and life 
expectancy <1 year due to neoplasia.
Another key factor that may justify the use of CRT-P instead of 
CRT-D could be represented by the aetiology, as occurs with non-
ischaemic cardiomyopathy (NICM). Both the Cardiomyopathy Trial 
(CAT)7 and Amiodarone Versus Implantable Cardioverter-Defibrillator 
Trial (AMIOVIRT)8 used single- and dual-chamber ICDs, but neither trial 
showed any survival benefit of ICDs in patients with NICM. Importantly, 
these studies involved small numbers of patients.
In the Defibrillators in Non-Ischaemic Cardiomyopathy Treatment 
Evaluation (DEFINITE) study, in which 458 patients with NICM were 
randomised to medical therapy or an ICD, ICD therapy did not reduce 
total mortality, despite a significant reduction in SCD.9 In the recent 
Defibrillator Implantation in Patients With Non-ischaemic Systolic Heart 
Failure (DANISH) study, neither ICD nor CRT-D reduced total mortality 
in patients with NICM.10 Notably, only patients aged younger than 68 
years had a significant reduction of SCD and overall mortality by CRT-D 
compared with CRT-P/best medical therapy. These studies cast doubt 
on the relative benefit of CRT-D versus CRT-P in patients with NICM, 
despite the promising results in favour of ICD in the non-ischaemic 
setting by a recent meta-analysis.11
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New Developments
Some recent data by Leyva et al., who evaluated mid-wall cardiac 
fibrosis by cardiac magnetic resonance, showed that CRT-D was 
markedly superior to CRT-P in terms of total mortality, cardiovascular 
mortality, and all composite endpoints in those patients with mid-wall 
fibrosis, whereas no benefit from CRT-D over CRT-P was observed in 
those patients without mid-wall fibrosis with respect to any of the 
endpoints.12 These findings indirectly substantiate the results of a meta-
analysis by Disertori et al. indicating that late gadolinium enhancement 
by cardiac magnetic resonance is a powerful predictor of ventricular 
arrhythmic risk in patients with ventricular dysfunction, irrespective 
of aetiology.13 The prognostic power of late gadolinium enhancement 
is particularly strong in patients with severely depressed ejection 
fraction, which suggests its potential to improve patient selection for 
ICD implantation. However, to be put into practice, late gadolinium 
enhancement protocols need to be standardised with respect to 
execution modalities and the setting of diagnostic thresholds. 
New developments may also provide additional data and new insights. 
The value of electrophysiology testing in assessing the need for an ICD, at 
least in the ischaemic setting, continues to be debated.14 Such a possibility 
could further facilitate the selection of appropriate CRT-D candidates.
Recent studies using His bundle pacing could further revolutionise the 
field of CRT. In some cases, a significant improvement of functional 
capacity and ventricular function has been observed.15–17 
Whether and in which patients His bundle pacing may represent 
a suitable alternative to CRT remains to be determined. Similarly, 
whether improvement of the efficacy of CRT will be adequate to refute 
the need for an ICD in certain patients remains to be seen.
Conclusion
Currently, and in the absence of hard data to guide clinical practice in 
this respect, we have to rely on the recommendations by the 2013 (and 
2017) update of the American College of Cardiology/American Heart 
Association and 2016 European Society of Cardiology guidelines on 
heart failure, and recommend an ICD, with or without CRT, in patients 
with non-ischaemic or ischaemic (at least 40 days post-MI) heart 
failure, LVEF ≤35 %, and NYHA II/III.18,19 n
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